In Feb26, The US FDA accepted Roches Giredestrant NDA for ESR1-mutated, ER-positive advanced breast cancer Total Revenue: $60.4B Founded Year: 1886 Total Employees: 1,38,200 Headquarters: New Jersey, United States Market Cap: $581.22B Stock Exchange: NYSE JnJ is a diversified healthcare company with a strong pharmaceuticals segment (Innovative Medicine) alongside medical devices, focusing on oncology, immunology, neuroscience, and cardiovascular diseases
2020 Sep;11(9):1965-1982
For a while, these medicines were only available as injections, but the introduction of a GLP-1 in pill form, Rybelsus, has given patients a needle-free Ozempic alternative
The introduction of the revised Annex 1 of the EU GMP guidelines has raised the bar for sterile manufacturing at a time when speed is critical
Many patients report experiencing a rapid return of hunger within days of their last dose
Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis
